GSK in breach for misleading prescription information on Omjjara: industry body Ruchika Sharma16 April 2025 2:34 PM ISTLondon: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards in the marketing and...
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia Ruchika Sharma14 Nov 2024 1:15 PM ISTMississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or...
Novartis to acquire MorphoSys AG for EUR 68 per share or aggregate of EUR 2.7bn in cash Ruchika Sharma6 Feb 2024 12:30 PM ISTBasel: Novartis has announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a...
GSK gets positive EMA Committee opinion recommending Momelotinib for myelofibrosis patients with anaemia Ruchika Sharma15 Nov 2023 2:30 PM ISTLondon: GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
Momelotinib receives FDA approval for patients of myelofibrosis with anaemia Dr. Kamal Kant Kohli19 Sept 2023 8:00 PM ISTUSA: JAK inhibitor momelotinib (Ojjaara) has received approval from the US Food and Drug Administration (FDA) as the first therapy specifically for...
Medical Bulletin 19/September/2023 Isra Zaman19 Sept 2023 3:15 PM ISTHere are the top medical news of the day:Researchers uncover surprising side effects of common diabetes drug MetforminMetformin, a well-established...
FDA approves JAK inhibitor Momelotinib for Myelofibrosis in Anemic adults Isra Zaman19 Sept 2023 9:30 AM ISTThe US Food and Drug Administration (FDA) has approved momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary...
GSK gets USFDA nod for bone marrow cancer therapy Ojjaara Ruchika Sharma16 Sept 2023 11:54 AM ISTOjjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
GSK regulatory submission for myelofibrosis medicine momelotinib accepted for review by Japanese regulator Ruchika Sharma12 Sept 2023 11:29 AM ISTLondon: GSK plc has announced that the Ministry of Health, Labour and Welfare (MHLW), Japan, has accepted for review a new drug application (NDA) for...
USFDA extends review period of GSK Momelotinib by three months Ruchika Sharma17 Jun 2023 10:00 AM ISTLondon: GSK plc has announced that the US Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for...
Targeted therapy momelotinib significantly improves symptoms and anemia in patients with myelofibrosis Dr. Kamal Kant Kohli9 Feb 2023 9:30 AM ISTPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated...
EMA validates marketing authorization application for blood cancer oral treatment Momelotinib: GSK Ruchika Sharma5 Dec 2022 10:30 AM ISTMyelofibrosis is a rare blood cancer that results from dysregulated JAK-signal transducer and activator of transcription protein signalling and is...
